Moreover, it was found that IL-8 was significantly decreased in patients with refractory psoriatic arthritis treated with exogenous IL-36Ra, suggesting that the IL-36 axis is among the inflammatory pathways that are most relevant to refractory psoriatic arthritis.497 However, there is no clinical data showing the clinical efficacy of IL-36R-targeted therapies in psoriatic arthritis. This evidence concerns the gene IL1RL2 and psoriatic arthritis.